Für statistische Zwecke und um bestmögliche Funktionalität zu bieten, speichert diese Website Cookies auf Ihrem Gerät. Das Speichern von Cookies kann in den Browser-Einstellungen deaktiviert werden. Wenn Sie die Website weiter nutzen, stimmen Sie der Verwendung von Cookies zu.

Cookie akzeptieren
D'Arcy, Patrick F. / Peter G. Welling et al (Hrsg.). Mechanisms of Drug Interactions. Springer Berlin Heidelberg, 2011.
eng

Mechanisms of Drug Interactions

  • Springer Berlin Heidelberg
  • 2011
  • Taschenbuch
  • 384 Seiten
  • ISBN 9783642646584
Herausgeber: Patrick F. D'Arcy / Peter G. Welling / James C. Mcelnay

Over the years a number of excellent books have classified and detailed drug­ drug interactions into their respective categories, e.g. interactions at plasma protein binding sites; those altering intestinal absorption or bioavailability; those involving hepatic metabolising enzymes; those involving competition or antagonism for receptor sites, and drug interactions modifying excretory mechanisms. Such books have presented extensive tables of interactions and their management. Although of considerable value to clinicians, such publica­ tions have not, however, been so expressive about the individual mechanisms that underlie these interactions. It is within this sphere of "mechanisms" that this present volume specialises. It deals with mechanisms of in vitro and in

Mehr Weniger
vivo, drug-drug, drug­ food and drug-herbals interactions and those that cause drugs to interfere with diagnostic laboratory tests. We believe that an explanation of the mechanisms of such interactions will enable practitioners to understand more fully the nature of the interactions and thus enable them to manage better their clinical outcome. If mechanisms of interactions are better understood, then it may be pos­ sible for the researcher to develop meaningful animal/biochemical/tissue cul­ ture or physicochemical models to which new molecules could be exposed during their development stages. The present position, which largely relies on patients experiencing adverse interactions before they can be established or documented, can hardly be regarded as satisfactory. This present volume is classified into two major parts; firstly, pharmacoki­ netic drug interactions and, secondly, pharmacodynamic drug interactions.

in Kürze